Lizely Finance Earnings Analysis — ANI Pharmaceuticals Interim Filing: Profit-to-Profit Growth on Both Windows

Bottom line

). ). ).

). ). ).

). ). - This analysis covers ANI PHARMACEUTICALS INC (ticker ANIP, CIK 0001023024), filing form 10-Q for fiscal period period-ended-2026-06-30, filed under accession 0001023024-26-000069, comparing the three months ended June 30, 2026 and the six months ended June 30, 2026 against their prior-year comparatives the three months ended June 30, 2025 and the six months ended June 30, 2025.

). - A useful parallel is REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in Filing, which shows the same profit-to-profit direction on revenue and net income at another interim reporter.

Financial performance

- Reported facts: - For the three-month reporting period, Revenue from Contract with Customer, Excluding Assessed Tax was $266,044,000 USD, higher than the prior-year comparative of $211,371,000 USD for the prior-year three-month reporting period. - For the six-month year-to-date period, Revenue from Contract with Customer, Excluding Assessed Tax was $503,506,000 USD, higher than the prior-year comparative of $408,493,000 USD. - Operating Income (Loss) was $40,460,000 USD for the three-month reporting period, higher than $13,892,000 USD in the prior-year three-month period, and was $79,348,000 USD for the six-month year-to-date period, higher than $40,086,000 USD in the prior-year six-month period.

Both windows remained profitable, with no transition to a loss. - Net Income (Loss) Attributable to Parent was $24,711,000 USD for the three-month reporting period, higher than $8,549,000 USD in the prior-year three-month period, and was $54,203,000 USD for the six-month year-to-date period, higher than $24,230,000 USD in the prior-year six-month period. Both windows again stayed profitable.

05 per diluted share USD/SHARES in the prior-year six-month period. Diluted EPS remained in profit territory across both comparative windows. - These items appear in the condensed consolidated statements of operations within the interim filing under 10-Q for period-ended-2026-06-30, filed under accession 0001023024-26-000069 by ANI PHARMACEUTICALS INC (CIK 0001023024, ticker ANIP).

S. promotional emphasis from YUTIQ to ILUVIEN under its expanded DME and NIU-PS label. S.

GAAP using the same policies discussed in the most recent annual filing, and management explicitly identifies areas that require estimates — including variable consideration items such as chargebacks, administrative fees, rebates, returns, government rebates, inventory obsolescence allowances, intangible and financial instrument valuations, contingent consideration, contingent value rights, right-of-use assets and lease liabilities, credit-loss allowances, and depreciable lives of long-lived assets. - Management also notes the conditional inclusion of a forward-looking-statement disclaimer within the interim filing.

- Analyst inference: - Because revenue, operating income, net income, and diluted EPS each moved higher versus the prior-year period on both the three-month and six-month windows, the directional read across all four metrics is consistent rather than mixed, supporting a comparison baseline of broad-based year-over-year improvement rather than a single-line lift. - Stockholders' equity disclosures under the cited note provide a structural baseline for the balance-sheet side of the comparison, although this section focuses on income-statement performance.

- Counter-evidence: - The interim filing presents unaudited figures, and management cautions that interim results are not necessarily indicative of results for the full fiscal year. - The interim statements also explicitly carve out contingencies tied to estimates and contingent liabilities, which can introduce variability between reported and eventual realized amounts. - The filing evidence contains no peer or industry comparison.

- Unknowns: - The filing evidence does not attribute this change to any single cause. - The interim filing, as quoted, contains no explicit forward-looking guidance, revenue or earnings outlook, or quantitative target for upcoming periods, so any near-term expectation commentary is left to subsequent disclosures rather than this filing. - The reader-facing quarter-over-quarter direction on each line item is not separately addressed in the quoted material; this section therefore limits its claim to year-over-year movement that the catalog is permitted to assert, as also seen in the REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in Filing reference case.

Operating drivers and segments

The filing does not present a multi-segment revenue breakdown for ANI PHARMACEUTICALS INC in the excerpted evidence; the income-statement disclosures center on a single operating entity. Reported Revenue from Contract with Customer, Excluding Assessed Tax was $266,044,000 USD for the three months ended June 30, 2026 and $503,506,000 USD for the six months ended June 30, 2026, each higher than the prior-year comparative of $211,371,000 USD and $408,493,000 USD respectively, consistent with the authorized quarter-over-quarter and half-year-over-half-year top-line direction. Operating Income (Loss) was $40,460,000 USD for the three months ended June 30, 2026 and $79,348,000 USD for the six months ended June 30, 2026, both higher than the prior-period figures of $13,892,000 USD and $40,086,000 USD, again aligned with the authorized direction. Because the section is restricted to revenue and operating income, and the excerpted text does not break out product-level or geographic profitability, no separate segment margin table is reproducible here; the operating result is reported only at the consolidated level.

Management frames the operating environment through forward-looking commentary in the cautionary statement that accompanies 10-Q for period-ended-2026-06-30. The narrative highlights the recent FDA label expansion for ILUVIEN to include non-infectious uveitis affecting the posterior segment of the eye in addition to the existing Diabetic Macular Edema indication, and references a forthcoming ASU on disaggregation of income statement expenses that the FASB issued in November of the comparative year, though the catalog does not provide quantitative weight for either item in this filing. Forward-looking statements cover planned operations, financial performance estimates, capital requirements, pipeline activities, anticipated FDA submission timing, patient-population and reimbursement expectations, manufacturing and supply-chain posture, branded-product selling strategy for Cortrophin Gel and ILUVIEN, competitive dynamics, strategic initiatives, intellectual property, and broader macro and regulatory factors including the One Big Beautiful Bill Act. Management does not, in the excerpted text, attribute the reported revenue or operating income movement to a specific driver such as price, volume, mix, or cost; the cautionary list enumerates possibilities rather than confirming causation. The filing evidence does not attribute this change to any single cause.

Cash flow and capital

- Reported balance sheet anchors at the instant date in the filing for ANI PHARMACEUTICALS INC (ANIP, 10-Q for period-ended-2026-06-30, accession 0001023024-26-000069) show cash on hand of $360,212,000 against long-term debt, excluding the current portion, of $280,155,000, leaving a clearly negative net-cash position after long-dated obligations only. - On the cash flow statement for the six-month year-to-date window the six months ended June 30, 2026, operating activities generated $115,044,000 of cash, a higher inflow than the $110,803,000 reported for the prior-year comparative period the six months ended June 30, 2025, consistent with the authorized direction of an increase.

- Investing activities for the six months ended June 30, 2026 absorbed -$14,378,000 of cash, a smaller outflow than the -$26,755,000 reported for the six months ended June 30, 2025, consistent with the authorized direction of an increase (that is, less cash used than a year earlier). - Within those investing outflows, capital spending on property, plant and equipment for the six months ended June 30, 2026 was $9,128,000, a higher figure than the $6,488,000 for the prior-year comparative, consistent with the authorized direction of an increase.

- Financing activities for the six months ended June 30, 2026 consumed -$26,263,000 of cash, a larger outflow than the -$11,653,000 reported for the six months ended June 30, 2025, consistent with the authorized direction of a decrease (more cash used in financing than a year earlier). - The financing detail breaks into two visible capital-return lines. Common stock buybacks for the six months ended June 30, 2026 totaled $20,568,000, a higher amount than the $10,554,000 reported for the prior-year comparative, consistent with the authorized direction of an increase.

Cash dividends for the six months ended June 30, 2026 were $0, a smaller figure than the $813,000 reported for the prior-year comparative, consistent with the authorized direction of a decrease (from a positive cash outflow for dividends to a zero cash outflow in the current window). - The narrative framing the cash flow statement notes that the unaudited interim condensed consolidated figures are not necessarily indicative of full-year results and that the interim disclosures should be read together with the most recent Annual Report on Form (omitted), the same cross-reference that governs other sections of this analysis.

- Analyst inference: combining the three streams, operating cash generation moved higher while investing outflows narrowed and financing outflows widened, with the financing widening concentrated in share repurchases rather than dividends, leaving a capital allocation posture tilted toward buybacks over cash returns to shareholders in the period. - Counter-evidence or read-across: the balance sheet shows a net-cash deficit after long-term debt at the instant date, which tempers the read on headline operating cash generation because the company remains funded partly by obligations outside the current portion.

- Unknowns: the filing does not break out the dividend line item in a way that explains the move to a zero cash outflow for dividends in the current window. The filing evidence does not attribute this change to any single cause. - Unknowns: the filing provides no peer or industry comparison for any of these cash flow or balance sheet lines.

The filing evidence contains no peer or industry comparison. - Analysts building capital-allocation models on this period can pair the cash flow read with the Lizely Finance Earnings Analysis — UFP TECHNOLOGIES INC Interim Filing for a cross-company sanity check on interim buyback-versus-dividend behavior.

Peer and historical context

- Reported revenue for the three months ended June 30, 2026 is higher than the prior-year the three months ended June 30, 2025, which is consistent with the half-year pattern of revenue being higher than the six months ended June 30, 2025; both windows show authorized profit-to-profit transitions on the top line, so the quarter and half-year readings reinforce each other rather than contradict one another. - Reported revenue for the six months ended June 30, 2026 is higher than the prior-year the six months ended June 30, 2025, aligning with the authorized transition; the half-year comparison is the broader frame, while the quarter comparison offers a single-period snapshot within that frame. - Reported operating income for the three months ended June 30, 2026 is higher than the prior-year the three months ended June 30, 2025, with an authorized profit-to-profit transition; the same direction is visible on the half-year comparison, where reported operating income for the six months ended June 30, 2026 is higher than the prior-year the six months ended June 30, 2025, again with an authorized profit-to-profit transition. - Reported net income for the three months ended June 30, 2026 is higher than the prior-year the three months ended June 30, 2025, with an authorized profit-to-profit transition; the half-year comparison shows the same direction, with reported net income for the six months ended June 30, 2026 higher than the prior-year the six months ended June 30, 2025 under an authorized profit-to-profit transition. - Reported operating cash flow for the six months ended June 30, 2026 is higher than the prior-year the six months ended June 30, 2025, which is consistent with higher operating income in the same half-year frame; the relationship between cash generation and reported profit is directionally supportive across both windows.

- The filing evidence contains no peer or industry comparison, so any cross-company read across the pharmaceutical generics, rare-disease, and branded portfolio is unavailable in this filing alone. - The filing evidence does not attribute any quarter-over-quarter or year-over-year movement to a single cause, so further driver commentary beyond the authorized direction labels is not supported here. - Quarter-to-quarter within the current fiscal year is not directly available from the cataloged facts, so the discussion is anchored strictly to the quarter-versus-prior-year-quarter and half-year-versus-prior-year-half-year windows rather than to a sequential quarter-on-quarter move.

For ANI PHARMACEUTICALS INC (ANIP) in this 10-Q for period-ended-2026-06-30 (filed under 0001023024-26-000069), the year-over-year picture is one in which revenue, operating income, net income, and operating cash flow are all higher than their prior-year comparatives, with the authorized transition reading profit to profit on each income-statement and cash-flow line. The quarter comparison is consistent with the half-year comparison, and the authorized direction on each line points the same way across both windows, which is the strongest internal coherence this cataloged evidence can support. A reader looking to compare this pattern against other interim filers can contrast it with REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in period-ended-2026-06-30 Filing and with Lizely Finance Earnings Analysis — UFP TECHNOLOGIES INC Interim Filing: Profit-to-Profit Growth on Both Windows, where the same profit-to-profit transition language is used; outside those cross-references, The filing evidence contains no peer or industry comparison. applies, and any further peer commentary would have to be sourced beyond this filing. Where the evidence does not speak to a single cause, The filing evidence does not attribute this change to any single cause..

Scenario analysis

The base case for ANI PHARMACEUTICALS INC (the ANIP filing on 10-Q for period-ended-2026-06-30, accession 0001023024-26-000069) anchors on a continuation of the authorized profit-to-profit trajectory already visible in the headline P&L. Revenue from Contract with Customer, Excluding Assessed Tax of $266,044,000 for the three months ended June 30, 2026 sits higher than the prior-year reading of $211,371,000 for the three months ended June 30, 2025, and the half-year revenue line of $503,506,000 for the six months ended June 30, 2026 likewise extends higher than $408,493,000 for the six months ended June 30, 2025, consistent with the disclosed revenue-recognition cadence where point-in-time product sales dominate and milestone or royalty lines fall in only as earned. Net Income (Loss) Attributable to Parent of $24,711,000 for the three months ended June 30, 2026 carries forward as a profit against the prior-year profit of $8,549,000, and the half-year figure of $54,203,000 for the six months ended June 30, 2026 likewise registers a profit-on-profit move from $24,230,000 for the six months ended June 30, 2025. The base reading treats milestone receipts under the Harmony Agreement, royalty streams from the pitolisant franchise, and the existing generic, rare-disease, and brands portfolio as broadly repeatable contributors, with no incremental catalysts and no incremental headwinds layered in beyond what is already evident in the reported lines.

An upside reading leans on the structural drivers the filing itself highlights. The Harmony Agreement is presented as carrying both a low-single-digit royalty stream on net sales of pitolisant-based products and a pipeline of development milestones that the Company recognizes as the milestones are achieved, and the period captures revenue associated with the achievement of development milestones alongside the upfront license fee already booked in an earlier quarter. In an upside construct, the cadence of those milestones accelerates and the royalty contribution widens as the pitolisant indication set expands beyond sleep/wake, lifting the revenue line above the half-year base of $503,506,000 while the quarter-level revenue print of $266,044,000 extends further above $211,371,000. On earnings, the upside case takes the profit conversion of the existing authorized move — the current quarter net income line of $24,711,000 relative to $8,549,000, and the half-year net income line of $54,203,000 relative to $24,230,000 — and layers in incremental milestone catch-up plus any operating leverage as product mix shifts toward higher-margin franchise assets. The filing evidence does not attribute this change to any single cause.

The downside case does not require a new driver; it only requires the disclosed revenue cadence to underperform the authorized base. If the royalty run-rate from pitolisant contracts and the milestone pipeline under the Harmony Agreement both thin out, the quarter revenue line of $266,044,000 could compress toward the prior-year reading of $211,371,000, and the half-year revenue line of $503,506,000 could similarly drift back toward $408,493,000. Because the authorized transition is profit-to-profit, a downside still keeps the bottom line positive, but the profit-on-profit move on net income — quarter $24,711,000 against $8,549,000 and half-year $54,203,000 against $24,230,000 — would narrow rather than extend. The pending accounting items noted in the cited note (the in-process evaluation of recently issued ASUs around hedge-accounting improvements) are flagged by management without a quantified impact and therefore do not shift the downside framing in either direction. The filing evidence does not attribute this change to any single cause.

Risks and what to watch

- Management commentary emphasizes point-in-time revenue recognition and royalty/milestone recognition tied to the Harmony Agreement, yet the snapshot provided in this filing shows only the headline revenue totals without any disaggregation of royalty versus product versus milestone streams, leaving investors unable to judge how much of the current-period top line depends on milestone payments that may not repeat. - Because the filing does not break out segment revenue or product mix, the durability of the reported $266,044,000 and $503,506,000 figures against the prior-year $211,371,000 and $408,493,000 bases cannot be assessed at a category level; The filing evidence does not disclose segment-level detail for this dimension.

governs here. - The profitability picture shows that $24,711,000 and $54,203,000 both sit higher than the $8,549,000 and $24,230,000 comparatives, but the filing offers no commentary on margin movement or operating leverage; The filing evidence does not attribute this change to any single cause.. - No peer or industry benchmark is included, so investors cannot judge whether the quarter-over-quarter improvement in revenue and net income reflects company-specific execution or sector-wide dynamics; The filing evidence contains no peer or industry comparison..

- Risk-factor language and legal proceedings discussed in the cited note under Item 1A have not been quoted in the available narrative; whether any new exposure, litigation outcome, or regulatory matter arose during the three months ended June 30, 2026 remains unstated. - The cited stockholders' equity note Note 12 is referenced for share-par disclosures only, and the filing does not flag any subsequent event, covenant breach, or material change that would reframe the quarter as out of the ordinary. - Variable consideration estimates are updated each reporting period based on historical data, contractual terms, and management judgment about market conditions, which is a recurring source of estimation risk; investors should watch whether management revises those estimates in the next period.

- Royalty revenue under the Harmony Agreement is described as low-single-digit on net sales of pitolisant-based products, which means a meaningful slice of recurring revenue depends on Harmony's commercial trajectory; deterioration there would not be visible until disclosed. - The financing-component policy notes payment terms generally within a short window, suggesting limited customer-credit risk in the revenue model itself, but this conclusion is qualitative and does not substitute for an explicit aging disclosure.

- Watch next quarter for any incremental disclosure about milestone revenue cadence under the Harmony Agreement, since the six-month period captured an explicit milestone recognition event that may not repeat at the same magnitude. - Watch next quarter for any commentary that ties reported revenue acceleration to specific products, channels, or territories; the present filing offers none, leaving causality open; The filing evidence does not attribute this change to any single cause.. - Watch next quarter for the next refresh of risk factors under Item 1A and for any updates to legal proceedings and controls language under Item 1 and Item 4 that could shift the risk profile relative to this period.